VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
COLL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
COLLCollegium Pharmaceutical, Inc.
$25.55$841M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCOLLBalance Sheet

Collegium Pharmaceutical, Inc. (COLL) Balance Sheet

13Y historyFree accessUpdated daily

Total debt of about $1.1B against equity of $296.4M yields a debt-to-equity ratio of 3.67 and a current ratio that fell to 1.01, which suggests leverage remains structurally high with a thin liquidity buffer.

Income StatementBalance SheetCash FlowRatios

COLL Balance Sheet

Annual statement

COLL Balance Sheet

Collegium Pharmaceutical, Inc. (COLL) balance sheet — 13-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Total Current Assets611.75M691.41M482.26M537.6M419.99M315.54M277.89M255.72M237.51M133.48M158.57M96.88M4.5M8.26M
Cash & Short-Term Investments144.8M406.53M162.76M310.55M173.69M186.43M174.12M170.02M146.63M118.7M153.22M95.7M1.63M7.55M
Cash Only144.8M251.1M70.56M238.95M173.69M186.43M174.12M170.02M146.63M118.7M153.22M95.7M1.63M7.55M
Short-Term Investments0155.43M92.2M71.6M0000000000
Accounts Receivable310.79M211.33M228.54M179.53M183.12M105.84M83.32M72.95M77.95M9.97M2.13M000
Days Sales Outstanding115.9698.82132.1115.61144.07139.5498.189.75101.46127.78454.17---
Inventory88.2M40.91M35.56M32.33M46.5M17.39M15.61M9.64M7.82M1.81M1.32M000
Days Inventory Outstanding77.9347.0651.0849.0566.7150.2943.7818.1717.22255.012.26K---
Other Current Assets19.85M3.24M27.74M93K57K27K60K141K1.01M456K304K558K2.82M0
Total Non-Current Assets1.48B965.42M1.18B605.71M754.14M376.53M365.95M50.58M53.73M2.08M3.44M835K594K773K
Property, Plant & Equipment15.29M16.2M20.15M22.01M26.38M27.14M27.38M20.9M9.27M1.83M1.04M738K514K693K
Fixed Asset Turnover52.96x48.18x31.34x25.75x17.59x10.20x11.32x14.20x30.24x15.59x1.65x---
Goodwill193.88M145.93M162.33M133.86M133.69M000000000
Intangible Assets1.13B669.51M891.4M421.71M567.47M268.72M335.9M29.5M44.26M02.1M000
Long-Term Investments1.06M1.06M002.55M2.55M00097K97K97K00
Other Non-Current Assets14.21M20.19M9.41M1.87M100K87K2.67M178K204K161K301K080K80K
Total Assets2.1B1.66B1.66B1.14B1.17B692.08M643.84M306.3M291.25M135.57M162.02M97.72M5.09M9.03M
Asset Turnover0.43x0.47x0.38x0.50x0.40x0.40x0.48x0.97x0.96x0.21x0.01x---
Asset Growth %65.36%-0.41%45.51%-2.63%69.65%7.49%110.2%5.17%114.83%-16.32%65.8%1819.8%-43.66%-
Total Current Liabilities603.09M440.03M509.51M457.92M433.73M279.57M239.45M201.76M187.48M31.49M22.93M5.76M10.42M2.62M
Accounts Payable10.43M10.66M3.93M8.69M3.49M4.19M10.02M6.25M12.15M5.68M9.11M3.54M2.21M1.22M
Days Payables Outstanding10.1612.265.6513.195.0112.1128.0811.7726.77799.4815.6K7.55K--
Short-Term Debt60.5M30.41M64.58M183.33M162.5M48.35M47.49M3.83M1.64M1.48M2.67M2.67M6.19M333K
Deferred Revenue (Current)3.78M667K0988K0000004.94M-9.55M00
Other Current Liabilities15.74M378.73M7.61M253.91M1.51M851K1.42M5.7M167.7M18.21M4.29M661K1.38M619K
Current Ratio1.01x1.57x0.95x1.17x0.97x1.13x1.16x1.27x1.27x4.24x6.92x16.81x0.43x3.16x
Quick Ratio0.87x1.48x0.88x1.10x0.86x1.07x1.10x1.22x1.23x4.18x6.86x16.81x0.43x3.16x
Cash Conversion Cycle183.74133.62177.53151.48205.76177.71113.7996.1591.91-416.7-12.89K---
Total Non-Current Liabilities1.2B915.13M925.24M489.96M545.56M209.58M218.36M17.11M12.18M7.16M4.18M6.88M6.91M834K
Long-Term Debt1.02B906.02M787.9M483.84M538.45M201.63M209.59M7.67M9.86M01.48M4.15M6.81M640K
Capital Lease Obligations15.23M4.13M5.54M6.12M7.11M7.95M8.77M9.44M0034K68K101K135K
Deferred Tax Liabilities60.93M0000000000000
Other Non-Current Liabilities142.93M-4.13M121.8M00000676K000059K
Total Liabilities1.8B1.36B1.43B947.88M979.29M489.15M457.81M218.87M199.66M31.49M27.11M12.65M17.33M3.45M
Total Debt1.09B940.56M859.3M674.28M709.17M258.75M266.58M21.59M11.5M1.48M4.15M6.81M13.01M973K
Net Debt942.21M689.46M788.73M435.34M535.49M72.32M92.47M-148.43M-135.13M-117.22M-149.08M-88.88M11.37M-6.58M
Debt / Equity3.67x3.12x3.75x3.45x3.64x1.28x1.43x0.25x0.13x0.01x0.03x0.08x-0.17x
Debt / EBITDA3.60x2.28x2.53x2.13x4.12x2.99x2.26x-0.13x-----
Net Debt / EBITDA3.12x1.67x2.33x1.38x3.11x0.84x0.79x--1.50x-----
Interest Coverage1.26x2.13x2.33x1.91x0.54x0.84x1.95x-24.00x-0.94x--1000.87x-61.08x-70.10x-212.12x
Total Equity296.44M301.68M228.84M195.43M194.84M202.93M186.03M87.43M91.58M104.08M134.91M85.07M-12.24M5.58M
Equity Growth %107.29%31.83%17.1%0.3%-3.98%9.08%112.77%-4.53%-12.01%-22.85%58.58%794.98%-319.29%-
Book Value per Share7.587.605.664.685.764.945.292.612.783.445.566.28-1.640.75
Total Shareholders' Equity296.44M301.68M228.84M195.43M194.84M202.93M186.03M87.43M91.58M104.08M134.91M85.07M-12.24M5.58M
Common Stock42K41K40K38K37K36K35K34K33K33K29K21K8K1K
Retained Earnings-79.92M-101.13M-164M-233.19M-281.34M-256.34M-333.15M-359.9M-337.18M-298.05M-223.18M-129.01M-101.75M-80.54M
Treasury Stock-262.51M-222.51M-197.5M-137.38M-61.92M-42.86M00000-3K-3K-3K
Accumulated OCI0319K55K14K00000-1.67M-1.33M-1.07M-903K-716K
Minority Interest00000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetStrained
Cash FlowStable
Top Statement Risk

Leverage limits shortfall tolerance

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Rebuilding Lags Rising Liabilities

Based on reported figures, COLL's equity rose from $216.6M in 2024Q2 to $296.4M in 2026Q3, while total liabilities climbed to $1.8B, so the balance sheet is strengthening in absolute terms but still carries leverage that grew faster than capital.

The equity build is largely the product of retained earnings moving from deeply negative territory toward -$79.9M, which suggests the accumulated deficit is narrowing but not yet reversed. Total assets expanded by roughly $1.0B over the period, driven mainly by acquired goodwill and intangibles, indicating that the asset base reflects purchased rather than organically built value. Investors should monitor whether earnings retention can keep pace with liability growth, since the current trajectory appears dependent on acquisition financing.

Elevated Leverage Persists Despite Deleveraging Attempts

As reported in financial statements, COLL's debt-to-equity ratio stood at 3.12 in 2025Q4 and 3.67 in 2026Q3, with total debt near $1.1B against equity of roughly $296M, indicating leverage that remains structurally high.

Debt rose from about $559M in 2024Q2 to roughly $1.1B in 2026Q3, and the 2026Q2 figure of $857.8M followed by a 2026Q3 reading of $1.1B suggests new borrowing rather than repayment. The leverage appears acquisition-driven instead of operationally necessitated, which may indicate a deliberate portfolio expansion strategy. Refinancing exposure and the cost of servicing this debt warrant further investigation, particularly given the narrow net margin of 8.1%.

Thin Liquidity Buffer Against Shocks

Based on reported figures, COLL's current ratio fell to 1.01 in 2026Q3 from 1.71 in 2026Q1, while cash of $144.8M sits against roughly $1.1B of debt, leaving a limited buffer relative to obligations.

The current ratio decline across recent quarters suggests short-term obligations are growing faster than liquid resources, despite cash rebounding from $39.0M in 2024Q3. Cash coverage of total debt is modest, which may constrain flexibility if revenue growth stalls or regulatory pressures intensify. This appears to make the company more dependent on continued operating cash generation than on balance sheet reserves.

Goodwill-Heavy Asset Base Limits Tangible Backing

According to reported balance sheet data, COLL's goodwill of $193.9M and net PP&E of only $15.3M indicate that the asset base is dominated by acquired intangibles and intangible-linked value rather than physical productive capacity.

The minimal PP&E relative to total assets of $2.1B is consistent with an asset-light specialty pharma model, where value resides in product rights and label exclusivity. The reliance on acquired intangibles means impairment risk is a material consideration if portfolio economics deteriorate. Tangible equity is negative once intangibles are excluded, which suggests creditor protection depends on the continued cash flow of the acquired franchises.

Deferred Revenue Offers Limited Forward Signal

Based on reported figures, COLL's deferred revenue fell from $20.0M in 2025Q1 to $10.4M in 2026Q3, with a 2026Q1 reading of only $667K, providing little evidence of a growing contracted revenue backlog.

The decline in deferred revenue suggests reduced advance billing or prepayment activity, which may indicate that near-term revenue visibility rests mainly on prescription run-rates rather than contracted commitments. The volatility of this line, including the near-zero 2026Q1 figure, makes it an unreliable forward indicator on its own. Investors may need to rely on prescription trends and guidance commentary to assess forward revenue durability.

Cash Generation Masks Leverage Exposure

Based on reported figures, COLL's cumulative operating cash flow of roughly $636M over ten quarters appears strong, yet a debt-to-equity ratio of 3.12 suggests that cash generation may overstate true financial flexibility.

Operating cash flow substantially exceeds reported net income, which points to heavy non-cash amortization and may make the operating picture look healthier than the balance sheet supports. Much of the cash generated appears directed toward acquisitions rather than debt reduction, so headline cash strength may not translate into balance sheet resilience. If revenue growth stalls further, the combination of high leverage and acquisition-dependent growth may limit management's options.

COLL — Frequently Asked Questions

Quick answers to the most common questions about buying COLL stock.

What are the total assets of Collegium Pharmaceutical, Inc. (COLL)?

As of 2025, Collegium Pharmaceutical, Inc. (COLL) had total assets of $1.66B including $691.4M in current assets.

How much debt does Collegium Pharmaceutical, Inc. (COLL) have?

Collegium Pharmaceutical, Inc. (COLL) carries total debt of $940.6M, offset by $406.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Collegium Pharmaceutical, Inc.?

Collegium Pharmaceutical, Inc. (COLL) has total shareholders' equity (book value) of $301.7M ($7.60 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Collegium Pharmaceutical, Inc.'s current ratio and liquidity?

Collegium Pharmaceutical, Inc. (COLL) reported a current ratio of 1.57x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.